The decrease in healthcare-associated methicillin-resistant Staphylococcus aureus infections and savings from glycopeptide use

We evaluated changes in the rate of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infections and healthcare-associated S. aureus infections after implementation of infection control precautions and the effect of this on glycopeptide use and expenditures for glycopeptides i...

Full description

Saved in:
Bibliographic Details
Published inInfection control and hospital epidemiology Vol. 27; no. 10; p. 1131
Main Authors Coskun, Diler, Aytac, Jale
Format Journal Article
LanguageEnglish
Published United States 01.10.2006
Subjects
Cross Infection - drug therapy
Cross Infection - epidemiology
Glycopeptides - economics
Glycopeptides - therapeutic use
Humans
Methicillin Resistance
Staphylococcal Infections - drug therapy
Staphylococcal Infections - epidemiology
Turkey - epidemiology
Turkey
Online AccessGet more information

Cover

More Information
Summary:We evaluated changes in the rate of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infections and healthcare-associated S. aureus infections after implementation of infection control precautions and the effect of this on glycopeptide use and expenditures for glycopeptides in a private medical center in Turkey in the years 2000-2005. A striking decrease was obtained in the number of MRSA infections, and the expenditure for glycopeptide use also decreased.
ISSN:0899-823X
DOI:10.1086/507969